Trials / Completed
CompletedNCT04705519
Nab-paclitaxel Combined with Bevacizumab in the Treatment of Metastatic Extrapulmonary Neuroendocrine Carcinoma
A Prospective, Non-randomized, Multicenter, Phase II Study of Nab-paclitaxel Combined with Bevacizumab for Unresectable Recurrent or Metastatic Extrapulmonary Neuroendocrine Carcinoma
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 79 (actual)
- Sponsor
- Peking University · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This is an open-label, phase II study evaluating efficacy and safety of Nab-paclitaxel Combined With Bevacizumab for unresectable Recurrent or metastatic extrapulmonary neuroendocrine carcinoma.
Detailed description
Nab-paclitaxel Combined With Bevacizumab will be evaluated in participants who have had ≥ 1 line of previous treatment. The primary endpoint is the Overall Survival (OS).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Nab-paclitaxel Combined With Bevacizumab | Nab-paclitaxel 150mg/m2 ，iv drip, d1, Bevacizumab 5mg/kg, iv drip, d1, q2w. |
Timeline
- Start date
- 2021-01-05
- Primary completion
- 2024-09-30
- Completion
- 2024-09-30
- First posted
- 2021-01-12
- Last updated
- 2025-03-14
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT04705519. Inclusion in this directory is not an endorsement.